Table 4.
Dosimetric Changes at Weeks 3 and 6 in Bulky and Postoperative Groups.a,b
| Parameter | Mean Percentage Change From Baseline (Range) | P Value for Difference Between B Versus PO | ||||||
|---|---|---|---|---|---|---|---|---|
| B | PO | |||||||
| Week 3 | Week 6 | P Value | Week 3 | Week 6 | P Value | Week 3 | Week 6 | |
| CTV-HR mean dose | 1.9% (6 to −1) | 2.4% (6 to 0) | >.05 | 1.6% (3 to 0) | 1.8% (4 to −17) | > .05 | > .05 | > .05 |
| CTV-LR mean dose | 1.2% (3 to −1) | 2.4% (5 to −1) | .042 | 1.1% (3 to −18) | 1.7% (6 to −25) | > .05 | >.05 | > .05 |
| RP mean dose | 15.2% (71 to −8) | 16.4 % (76 to −30) | >.05 | 16.3% (89 to −13) | 9.1% (70 to −25) | > .05 | > .05 | > .05 |
| LP mean dose | 16.1% (50 to −2) | 15.8% (60 to −11) | >.05 | 6.3% (51 to −18) | 10.4% (56 to −18) | > .05 | > .05 | >.05 |
| SC maximum dose | 0.08% (21 to 0) | 0.06% (25 to −1) | >.05 | 0.03% (46 to −1) | 0.04% (13 to −1) | > .05 | (.052) | > .05 |
Abbreviations: B, bulky disease; CTV-HR, high-risk clinical target volumes; CTV-LR, low-risk clinical target volumes; LP, left parotid; RP, right parotid; PO, postoperative; SC, spinal cord.
a P value from 2-way analysis of variance (ANOVA) model with 1 fixed factor (group), 1 repeated-measures factor (week), and their interaction (group × week).
b P > .05: not significant. P ≤ .05: significant difference within groups, week 3 versus 6, or between groups, B versus PO, at a specific week (3 or 6).